Tempus AI (NASDAQ:TEM) CFO Sells $478,291.71 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 10,853 shares of the firm’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total transaction of $478,291.71. Following the completion of the transaction, the chief financial officer directly owned 126,395 shares of the company’s stock, valued at $5,570,227.65. This represents a 7.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Price Performance

NASDAQ:TEM opened at $46.18 on Friday. Tempus AI, Inc. has a 1-year low of $41.73 and a 1-year high of $104.32. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96. The firm has a fifty day simple moving average of $48.89 and a 200 day simple moving average of $59.29. The stock has a market capitalization of $8.29 billion, a PE ratio of -26.85 and a beta of 3.99.

Tempus AI (NASDAQ:TEM) last released its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The business had revenue of $348.12 million during the quarter, compared to analysts’ expectations of $345.44 million. During the same period last year, the business earned ($0.24) earnings per share. The firm’s revenue was up 36.1% on a year-over-year basis. On average, research analysts expect that Tempus AI, Inc. will post -1.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Tempus AI

Several hedge funds have recently added to or reduced their stakes in TEM. GC Wealth Management RIA LLC acquired a new stake in Tempus AI during the 4th quarter valued at $399,267,000. Vanguard Group Inc. lifted its holdings in Tempus AI by 22.1% during the 3rd quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock valued at $762,032,000 after purchasing an additional 1,706,837 shares during the last quarter. Voloridge Investment Management LLC lifted its holdings in Tempus AI by 183.0% during the 3rd quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock valued at $129,708,000 after purchasing an additional 1,039,176 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in Tempus AI by 312.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company’s stock valued at $102,869,000 after purchasing an additional 965,730 shares during the last quarter. Finally, AQR Capital Management LLC acquired a new stake in Tempus AI during the 2nd quarter valued at $54,020,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Wall Street Analysts Forecast Growth

TEM has been the subject of several analyst reports. Robert W. Baird initiated coverage on shares of Tempus AI in a research note on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 target price for the company. BTIG Research decreased their target price on shares of Tempus AI from $90.00 to $80.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Guggenheim cut their price target on Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a report on Monday, March 30th. Stifel Nicolaus set a $60.00 price target on Tempus AI in a report on Wednesday, February 25th. Finally, HC Wainwright cut their price target on Tempus AI from $95.00 to $64.00 and set a “buy” rating for the company in a report on Monday, May 11th. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $68.64.

Tempus AI News Roundup

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched the ArteraAI Prostate Test for metastatic patients, its first prostate digital pathology algorithm available for clinical use inside the Tempus ecosystem. The move expands its oncology platform and could deepen adoption with urologists and oncologists. Article Title
• Positive Sentiment: An analyst-style bullish take argued Tempus is benefiting from a large data estate, AI-driven products, and a contract backlog above $1 billion, suggesting the recent pullback may have created a more attractive valuation for risk-tolerant investors. Article Title

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.